Solid Biosciences DEF 14A: Executive Compensation Details
Ticker: SLDB · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1707502
| Field | Detail |
|---|---|
| Company | Solid Biosciences Inc. (SLDB) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, sec-filing
TL;DR
Solid Biosciences dropped its proxy statement detailing exec pay for 2024. Check out stock awards for Ganot & Cumbo.
AI Summary
Solid Biosciences Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on stock awards granted and outstanding, as well as changes in the fair value of these awards for individuals like Ilan Ganot and Alexander Cumbo. It also outlines equity awards for non-executive officers.
Why It Matters
This filing provides transparency into how Solid Biosciences compensates its top executives, which can influence investor decisions and employee morale.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the details on executive compensation can sometimes reveal underlying company performance or strategic shifts that may impact stock value.
Key Numbers
- 2024 — Fiscal Year (Period covered by the executive compensation disclosures)
- 2023 — Fiscal Year (Comparative compensation data)
- 2022 — Fiscal Year (Comparative compensation data)
Key Players & Entities
- Solid Biosciences Inc. (company) — Filer of the DEF 14A
- Ilan Ganot (person) — Executive mentioned in compensation details
- Alexander Cumbo (person) — Executive mentioned in compensation details
- 2024-12-31 (date) — Fiscal year end for compensation reporting
- 20250425 (date) — Filing date of the DEF 14A
FAQ
What was the total compensation for Ilan Ganot in 2024?
The filing indicates that Ilan Ganot is a member and the reporting period for his compensation is the fiscal year 2024, but specific dollar amounts are not detailed in this excerpt.
What is the fair value of equity awards granted to Alexander Cumbo in 2024?
The filing mentions 'VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember' and 'YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember' for Alexander Cumbo for the 2024 fiscal year, but specific dollar values are not provided in this summary.
When did Solid Biosciences change its name from Solid Biosciences, LLC?
The date of name change from Solid Biosciences, LLC to Solid Biosciences Inc. was May 24, 2017.
What is the primary business of Solid Biosciences Inc.?
Solid Biosciences Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
What is the filing date of this DEF 14A?
This DEF 14A filing was made on April 25, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 by Ilan Ganot regarding Solid Biosciences Inc. (SLDB).